Muhammad ASHRAF, Muhammad ATHAR ABBASI, Aziz UR-REHMAN, Khadija NAFEESA, Sabahat ZAHRA SIDDIQUI, Shahid RASOOL, Syed ADNAN ALI SHAH, Muhammad Arif LODHI, Farman Ali KHAN, Bakhat JAHAN

S-substituted derivatives of 1,2,4-triazol-3-thiol as new drug candidates for type II diabetes

The therapeutic applications of 1,2,4-triazoles motivated us to synthesize some new derivatives. Two series ofS -substituted derivatives (8a–8j, 12a–12i) of 5-{1-[(4-chlorophenyl)sulfonyl]-3-piperidinyl}-4-phenyl-4H -1,2,4-triazol3-thiol (6) have been synthesized and evaluated for their biological potential. Using 4-chlorobenzene sulfonyl chloride(1) and ethyl piperidine-3-carboxylate (2), ethyl 1-[(4-chlorophenyl)sulfonyl]piperidine-3-carboxylate (3) was synthesizedand converted into 3,4,5-trisubstituted 1,2,4-triazole (6) through formation of the corresponding carbohydrazide (4) andhydrazinecarbothioamide (5). Compound 6 was transformed into 8a–8j by alkyl halides (7a–7j) and into 12a–12i byN -aralkyl/aryl-2-bromoacetamides (11a–11i) in an aprotic solvent. The electrophiles, 11a–11i, were synthesized bygearing up N -substituted aralkyl/aryl amines (10a–10i) with 2-bromoacetyl bromide (9) under dynamic pH control byaqueous sodium carbonate. Structures were elucidated through the spectral techniques of IR, EIMS, 1 H NMR, and 13 CNMR. Most of the synthesized derivatives were found to be potent inhibitors of α-glucosidase enzyme and even betterthan acarbose. Acarbose is a reference standard and is a commercially available α-glucosidase inhibitor to treat patientswith type II diabetes. The low hemolytic activity also emphasized the potential of the synthesized compounds as newdrug candidates.

PDF

___

1. Suma, A. R.; Padmalatha; Nayak, J.; Shetty, A. N. J. Metal. Mater. Sci. 2005, 47, 51-57.
2. Popova, I.; Yates, J. T. J. Langmuir 1997, 13, 6169-6175.
3. Kharb, R.; Sharma, P. C.; Yar, M. S. J. Enzyme Inhib. Med. Chem. 2011, 26, 1-21.
4. Chinthala, Y.; Thakur, S.; Tirunagari, S.; Chinde, S.; Domatti, A. K.; Arigari, N. K.; Srinivas, K. V. N. S.; Alam, S.; Jonnala, K. K.; Khan, F. et al. Eur. J. Med. Chem. 2015, 93, 564-573.
5. Faidallah, H. M.; Khan, K. A.; Asiri, A. M. J. Fluorine Chem. 2011, 132, 870-877.
6. Miniyar, P. B.; Mahajan, A. A.; Mokale, S. N.; Shah, M. U.; Kumar, A. S.; Chaturbhuj, G. U. Arabian J. Chem. 2017, 10, 295-299.
7. Bengtsson, C.; Lindgren, A. E. G.; Uvell, H.; Almqvist, F. Eur. J. Med. Chem. 2012, 54, 637-646.
8. Ferreira, S. B.; Sodero, A. C. R.; Cardoso, M. F. C.; Lima, E. S.; Kaiser, C. R.; Silva, F. P. Jr; Ferreira, V. F. J. Med. Chem. 2010, 53, 2364-2375.
9. Gong, Z.; Peng, Y.; Qiu, J.; Cao, A.; Wang, G.; Peng, Z. Molecules. 2017, 22, E1555.
10. Asif, M. Acta Velit. 2015, 1, 1-11.
11. Bruni, C. B.; Sica, V.; Auricchio, F.; Covelli, I. Biochim. Biophys. Acta 1970, 212, 470-477.
12. Nichols, B. L.; Avery, S. E.; Karnsakul, W.; Jahoor, F.; Sen, P.; Swallow, D. M.; Luginbuehl, U.; Hahn D.; Sterchi, E. E. J. Pediatr. Gastroenterol. Nutr. 2002, 35, 573-579.
13. van de Laar, F. A. Vasc. Health Risk Manag. 2008, 4, 1189-1195.
14. van de Laar, F. A.; Lucassen, P. L.; Akkermans, R. P.; van de Lisdonk, E. H.; Rutten G. E.; Weel, C. V. Diabetes Care 2005, 28, 154-163.
15. Abbasi, M. A.; Raza, N.; Aziz-ur-Rehman; Rasool, S.; Khan, K. M.; Ashraf, M.; Alam, U.; Nasar, R. World J. Pharm. Sci. 2014, 2, 161-169.
16. Abbasi, M. A.; Najm, S.; Aziz-ur-Rehman; Rasool, S.; Khan, K. M.; Ashraf, M.; Nasar, R.; Alam, U. Trop. J. Pharm. Res. 2015, 14, 47-54.
17. Abbasi, M. A.; Islam, M.; Aziz-ur-Rehman; Rasool, S.; Rubab, K.; Hussain, G.; Ahmad, I.; Ashraf, M.; Shahid, M.; Shah, S. A. A. Trop. J. Pharm. Res. 2016, 15, 591-598.
18. Sharma, P.; Sharma, J. D. J. Ethnopharmacol. 2001, 74, 239-243.
19. Powell, W. A.; Catranis, C. M.; Maynard, C. A. Lett. Appl. Microbiol. 2000, 31, 163-168.
20. Brueggeman, G. P.; Hollingsworth, R. I. Tetrahedron 2001, 57, 8773-8778.
21. Allouche, A. R. J. Comput. Chem. 2010, 32, 174-182.
22. Stewart, J. P. J. Mol. Model. 2007, 13, 1173-1213.
23. Trott, O.; Olson, A. J. J. Comput. Chem. 2010, 31, 455-461.